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Background Type 2 diabetes mellitus constitutes a global epidemic and a major burden on health care systems across the
world. Prevention of this disease is essential, and the development of effective prevention strategies requires validated infor-
mation on the disease burden and the risk factors. Embarking on a nationally representative cross-sectional study is challen-
ging and costly. Few countries undertake this process regularly, if at all.
Method This paper sets out the evidence-based protocol of a recent cross-sectional study that was conducted in Malta.
Data collection took place from November 2014 to January 2016.
Results This study presents up-to-date national data on diabetes and its risk factors (such as obesity, smoking, physical
activity and alcohol intake) that will soon be publicly available.
Conclusion This protocol was compiled so that the study can be replicated in other countries. The protocol contains step-
by-step descriptions of the study design, including details on the population sampling, the permissions required and the vali-
dated measurement tools used.
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Introduction
Type 2 diabetes mellitus (T2DM) is a global epidemic, and
the International Diabetes Federation (IDF) declared it a
‘global emergency’ in 2015. The estimated global prevalence
of T2DM in 2015 was 8.8% and this is predicted to rise to
10.4% by 2040 [1]. Across Europe, ageing, inadequate phys-
ical activity levels, high calorie diets and rising levels of obes-
ity continue to contribute to the disease, which has a
substantial impact on individuals’ quality of life [2].
Another established risk factor for diabetes is pre-diabetes,
where an individual’s blood glucose level is above the normal
level but not high enough for a diagnosis of diabetes [3].
Those with pre-diabetes are at an increased risk of develop-
ing diabetes, with a 5-year conversion rate from 10 to 23%
depending on the diagnostic criteria used [4]. Therefore, a
greater understanding of pre-diabetes is essential for the
prevention of diabetes [3]. In addition, identifying individuals
with pre-diabetes at an early stage can have a positive impact
on health outcomes [5].
In order for countries to be in a position to manage the
increasing burden of diabetes and to be able to develop
evidence-based prevention strategies, regular evaluations of
the prevalence of diabetes, its risk factors and its impact need
to be carried out at the national level [6]. The IDF has strongly
recommended that individual countries carry out research
(including prevalence studies) in order to obtain an accurate
and up-to-date picture of the local diabetes situation [1].
Malta is an archipelago of islands in the Mediterranean
Sea, at the crossroads between Europe and Africa, and it
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has been known to have a high prevalence of T2DM since
the 18th century [7]. It is a small archipelago of islands
(<316 km2) with an accessible population (<500 000 peo-
ple), which makes it a relatively easy location in which to
carry out nationally representative studies on diabetes and
other common non-communicable diseases. The increase
in the prevalence of diabetes in the country has been attrib-
uted to the shift in its population from a Mediterranean life-
style to a more Westernized lifestyle [8].
Prevalence studies are not conducted regularly in Malta.
Effectively, this study protocol is the only national cross-
sectional study on diabetes and its risk factors to be con-
ducted in the past 35 years [9]. Considering the extensive
changes in lifestyles, culture and demographics of the
Maltese population over the recent decades and considering
the improvements in genetic technology, conducting
national surveys of non-communicable diseases such as dia-
betes that utilize the advanced genetic technology is impera-
tive in order to gather up-to-data data [8]. These national
studies should also identify the most important current
risk factors for the disease in question.
The study based on this protocol was supported by
Malta’s Minister for Health who highlighted that it would
provide key evidence for the development of prevention
strategies and it would provide information to inform future
research [10]. As a result of the vital nature of the data col-
lected in the study, a campaign (with stringent ethical cri-
teria) to raise funds from academic and private sources
was launched, thereby avoiding the need to rely on the
extremely limited state funding.
The study was conducted by the University of Malta. It
was entitled ‘SAHHTEK’ (Your Health) – The University
of Malta Health and Wellbeing Study’ and it took place
from November 2014 to January 2016 with encouragement
and in-kind support from the government of Malta. The aim
of the study was to obtain up-to-date information on the
prevalence of T2DM in Malta, to investigate the pre-diabetic
population and to shed light on the important links between
pre-diabetes and diabetes and its determinants [11]. This
paper presents the study protocol and the lessons learnt
from the study in order to aid other countries that wish
to undertake a similar survey.
Deﬁnition of cases
The participants that had been previously diagnosed with dia-
betes and were on medication were categorized as having
diabetes irrespective of their fasting blood glucose (FBG)
levels. Participants who had not previously been diagnosed
but who had an FBG level of ≥7 mmol/L were categorized
as having newly diagnosed diabetes. This was in line with
the standard recommendations to use an FBG level of ≥7
mmol/L for the estimation of the prevalence of diabetes
(with no repeat testing if a diagnosis of diabetes is estab-
lished) [12–14]. Participants with an FBG level of 5.6–6.9
mmol/L who had not previously been diagnosed with diabetes
were categorized as having impaired fasting glucose (IFG) [11].
The FBG cut-off point of 5.6 mmol/L has been proven to be
the optimal value for the prediction of future diabetes [15].
Participants with a FBG level of <5.59 mmol/L were assumed
to have normal carbohydrate metabolism [12].
A 2-h oral glucose tolerance test (OGTT) was under-
taken by those who had IFG in order to assess whether
the participants had impaired glucose tolerance (IGT) or
diabetes (despite not having FBG levels of ≥7 mmol/L).
This is in line with the fact that approximately 31% of indi-
viduals with diabetes are not picked up by the FBG criteria
[13, 16]. In line with the OGTT cut-off criteria of the World
Health Organization (WHO), those with a 2-h blood glu-
cose level of 7.8–11.0 mmol/L were categorized as having
IGT, whereas those with a level of ≥11.1 mmol/L were cate-
gorized as having diabetes [13].
Sampling methodology
The sample was randomly selected from the ofﬁcial popula-
tion register in order to be representative of the Maltese
resident population (including foreign-born residents) who
had lived in Malta at least 6 months. The sample was selected
using a stratiﬁcation strategy which depended on age
(between 18 and 70), gender and location. Based on the
American Diabetes Association (ADA) estimate of the
prevalence of pre-diabetes (25%), the prevalence of pre-
diabetes in Malta was estimated to be 25% [17]. Since a pri-
mary aim of the study was to identify the subpopulation of
individuals with pre-diabetes, it was assumed that the size
of the sample would have to be approximately four times
the number of individuals with pre-diabetes required.
Should the prevalence of individuals with pre-diabetes in
Malta be higher than 25%, it would be to the study’s advan-
tage. Based on local health examination studies, a response
rate of around 50% was expected [18]. Therefore, the size
of the sample had to be eight times the required number
of individuals with pre-diabetes. In addition, as one of the
aims of the study was to explore the associations between
a large numbers of factors, for the purpose of sample size
estimation, it was assumed that the worst-case scenario
was a 50% response rate.
Using the PiFace® software with a maximum conﬁdence
interval of ±5%, it was estimated that a sample of 384 parti-
cipants with pre-diabetes should be recruited [17, 19].
Therefore, a minimum sample of 3072 had to be selected
from the population. In order to allow for a lower response
rate compared to that in Malta’s 2010 European Health
Examination Survey, and for deaths and emigration during
the ﬁeldwork period, a sample of 4000 was chosen [18].
This amounted to approximately 1% of the adult population
of Malta. In fact, the demographics of the study population
were similar to the representative data obtained from the
latest Maltese demographic report issued by Malta’s
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National Statistics Ofﬁce, as seen in Table 1 that demon-
strates the sample population in relation to the total popu-
lation of Malta by age groups [20].
The selection of a sample drawn from the population
register allowed nationally representative data to be col-
lected that means that conclusions can be drawn for the
whole population, and it also means that in-depth analyses
of subgroups (such as the diabetic and pre-diabetic sub-
groups) can be carried out. As single-stage random sampling
was used, there was no clustering effect. Pregnant female
participants were excluded from the survey
Permissions
Both the Research Ethics Committee of the Faculty of
Medicine and Surgery at the University of Malta and
Malta’s Information and Data Protection Commissioner
gave their permission for the study to be run. The
Ministry for Energy & Health, through the Parliamentary
Secretary and the Department of Primary Care, provided
support in the form of the use of local government health
clinics and the use of the Biochemistry Laboratory of the
public Mater Dei Hospital.
Recruitment of ﬁeldworkers
Interviewers and health assessors (who were trained phle-
botomists who collected the blood samples as well as carry-
ing out the health examinations) were recruited using
adverts in local newspapers. The ability to communicate in
both Maltese and English was considered to be essential.
Training sessions on the measurement tools were organized
quarterly to ensure that the assessments were conducted
uniformly to avoid inter- and intra-observer variability.
The interviewers underwent frequent revalidation of their
interviewing techniques to avoid biases and to ensure the
quality of the data.
Measurement tools
Invitation letters and consent forms were composed in
Maltese and English. Back translation from the English ver-
sion to Maltese version then back to English version was
performed. In line with the WHO STEPS framework, a vali-
dated questionnaire-based assessment, simple physical mea-
surements (blood pressure, height, weight and waist and hip
circumferences) and biochemical measurements (FBG, lipid
Table 1. Size of the study sample compared to the size of the national population in 2013
Age group Total populationa Total sample (approximately 1% of population)
18–24 40 564 504
25–34 62 180 747
35–44 56 575 725
45–54 55 113 749
55–64 59 268 804
65–70 33 480 471
Age group Male populationa Male sample (approximately 1% of population)
18–24 21 045 260
25–34 32 359 391
35–44 29 143 377
45–54 27 728 366
55–64 29 585 408
65–70 16 136 239
Age group Female populationa Female sample (approximately 1% of population)
18–24 19 519 244
25–34 29 821 356
35–44 27 432 348
45–54 27 385 383
55–64 29 683 396
65–70 17 344 232
a Demographic data from Malta’s National Statistics Ofﬁce.
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proﬁle and glucose tolerance, as measured using an OGTT
for the selected participants) were carried out [21]. The
questionnaire used was a composite of a number of vali-
dated tools, details of which are available in the online
Supplementary File. The validated measurement equipment
was calibrated in accordance with WHO regulations, details
of which can also be found in the online Supplementary
File [22].
Age of participants
The study aimed to assess the adult population in Malta. For
this reason and also to avoid the requirement for parental
consent, the lower age limit was set at 18. Even though
both pre-diabetes and T2DM are being diagnosed at increas-
ingly early ages in many countries, the prevalence in those
under 18 would still be relatively low compared with that
in the older population [23]. The upper age limit was set
at 70 years as beyond this age, the presence of long-standing
diabetes or incident disease is more common [24].
Approximately 20% of those older than 65 have diabetes
and studying older age groups may skew the true prevalence
of diabetes [25]. Research on diabetes in those aged over 70
has shown that glucose diagnoses and glucose control
showed no signiﬁcant cardiovascular disease reduction and
some studies even showed excessive deaths in those are
undergoing intensive glucose control [24].
Health examinations
The randomly selected participants were each asked to
attend an appointment at various locations in Malta, having
fasted for at least 9 h and having abstained from cigarette
smoking and physical activity for at least an hour. On regis-
tering, each participant was issued with a unique code. An
interviewer explained the consent form and allowed time
for the participant to read it and ask questions. If the subject
agreed to participate, the questionnaire was ﬁlled in by the
interviewer in accordance with the participant’s responses.
While still sitting down, three consecutive blood pressure
measurements were taken, and the third blood pressure
measurement was recorded (to reduce the impact of
white coat hypertension). This was followed by measure-
ments of weight and height using validated weighing scales
with a built-in height rod. The participants removed their
shoes and excess clothing and emptied their pockets. The
waist and hip circumferences were measured using a meas-
uring tape. The waist circumference was measured midway
between the lower rib margin and the iliac crest and the hip
circumference was measured at the tip of the iliac crest.
Sets of three venous blood samples were collected from
each participant for measuring FBG levels, for assessing lipid
proﬁles, and for carrying out a genotyping analysis. The
blood samples were collected by skilled phlebotomists,
using butterﬂy needles and a Vacutainer® system. Each
blood sample was labelled with the participant’s code and
put on ice in a cooler bag. Great care was taken with the
samples to avoid haemolysis or glycolysis. This involved
using preservative tubes and delivering them to the labora-
tory within 2 h of collection. This was feasible as Malta is
a very small country and the laboratory is in a central loca-
tion, so travelling distances were short.
Each participant was given a copy of all the results of the
measurements taken during the examination and they were
advised that they would receive a copy of their blood test
results by mail within a week and that their results should
be discussed with their general practitioner. They were
informed that, should their FBG level be 5.6–6.9 mmol/L,
this was considered to be a borderline result and so an
OGTT would be offered at a later date.
Blood tests
The assessments of FBG levels and lipid proﬁles were per-
formed at the Biochemistry Laboratory of the Mater Dei
Hospital. Automated and regularly quality controlled
COBAS INTEGRA® Analysers machines were used to
carry out the tests.
The fasting blood samples to be used to measure FBG
levels were collected in ﬂuoride-containing tubes in order
to minimize the levels of glycolysis. The FBG levels were
measured using hexokinase and glucose oxidase enzyme
reactions.
A serum clot activator tube was used to collect blood
samples for the lipid proﬁle assessment. This involved asses-
sing each participant’s total serum cholesterol, high-density
lipoprotein (HDL), low-density lipoprotein (LDL) and trigly-
cerides. These assessments were carried out in light of the
link between lipid parameters and diabetes, including the
association between the diagnostic criteria for metabolic
syndrome (which involves multiple lipid parameters) and
the development of T2DM [26]. At the time of formulating
this protocol, there was no clear consensus in the literature
as to the appropriate fasting period prior to lipid proﬁle
testing [27, 28]. Therefore, a 9-h fasting period was chosen
in line with the preliminary recommendations in the litera-
ture [29].
Using aliquots from each serum sample, the lipid variables
were measured as follows: HDL was measured using the
clearance method, triglycerides were measured using an
enzymatic colorimetric analysis with glycerol phosphate oxi-
dase and 4-aminophenazone total cholesterol was measured
using a cholesterol oxidase enzymatic reaction and LDL was
measured using the Friedewald formula.
A third venous blood sample was taken in an EDTA tube
and stored at −20 °C for later use in a genotyping analysis.
This would help us identify any links between different gen-
etic mutations and diabetes mellitus on a population level.
Those participants who were invited to undergo the
OGTT were advised to follow their regular diet before
the test but to fast the night and the morning before the
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test. An initial FBG sample was taken from each participant
in a ﬂuoride-containing tube. The participants were then
given 75 g of glucose and additional blood glucose samples
were collected after 1 and 2 h.
Data input and analysis
A single ﬁeldworker inputted the data in order to avoid bias.
The data inputting was performed using a secure online soft-
ware program that matched the format of the survey ques-
tionnaire and also allowed each participant’s measurements
to be added. The software was programmed to carry out
data validation (which included setting upper and lower lim-
its for the various variables such as age) to ensure the quality
of the data. The data were then transferred to a spreadsheet
program for analysis. The analysis was carried out using IBM
SPSS version 21 for Mac.
The participants’ questionnaires were cross-referenced
with the online versions to check the accuracy of the online
data. This process involved cross-referencing several ran-
domly selected questionnaires with the online version at
the end of each month.
Results
A number of lessons were learnt while conducting the sur-
vey, as shown in Table 2. A pilot test was conducted to iden-
tify each ﬁeldworker’s strengths and ensure that the
ﬁeldworkers focused on the tasks that they excelled in dur-
ing the actual survey. Another lesson learnt was that the
waist and hip circumferences should be measured after
the height and weight measurements. This was because
once the participants had removed all their excess clothes
and other items, it was easier to continue with the circumfer-
ence measurements and it helped to prevent inter-observer
variability. Care was taken to take each participant’s waist cir-
cumference measurement as the participant breathed out.
A health examination hub (where the interviews, collection
of blood samples and measurements took place) was set up
every weekend at different local government health clinics
situated throughout the Maltese Islands. Holding the health
examinations in each town health clinic was an effective
approach as the participants found it easier to attend when
they did not need to travel large distances. The randomly
selected participants from each town received a postal invita-
tion letter 2 weeks prior to their appointment, together with
an explanation of the aim of the study, the beneﬁts of attend-
ing, and an appointment date and time. Participants were
given the choice to change their appointment date and time
to a more suitable alternative (including a weekday appoint-
ment) and to attend a clinic in a different town. This ﬂexibility
encouraged those who wanted to attend to participate. The
early appointments (7.00 am–7.30 am) were found to be
favoured by those over 50, while the later appointments
(8.30 am–9.00 am) were favoured by the younger population.
The last appointment was set at 9.30 am for two reasons: par-
ticipants needed to be fasted so late appointments would not
be well tolerated and the blood samples needed to be taken
to the laboratory within 2 h after they were collected.
The interviews were challenging despite the fact that the
interviewers were well trained because there was a risk of
information bias as some of the answers depended on the
participants’ knowledge and memory skills.
At the end of the health examinations, participants often
expressed their gratitude for the experience, for being kept
informed of their measurement results throughout the pro-
cesses (where possible) and for being given a copy of their
measurement results.
Discussion
Regular cross-sectional prevalence studies of non-
communicable diseases can provide an evidence base to
aid public health professionals (including policy makers) in
developing strategies to prevent and manage the diseases.
Prevalence studies can be technically challenging, laborious
and expensive, so they are rarely conducted. Our protocol
used a multidisciplinary approach and was based on
up-to-date ﬁndings from the literature in order to collect
cross-sectional epidemiological data at minimal costs and
with a minimal number of ﬁeldworkers. The evaluation of
the study showed that the protocol set out an effective
method for obtaining high-quality data. Although the proto-
col focused on how to conduct a T2DM prevalence study
and to collect data on the determinants of this disease,
the protocol can be modiﬁed to accommodate the collec-
tion of data on other non-communicable diseases.
Study limitations
Although great care was taken to reduce bias, the study
involved data collected from people who may have provided
Table 2. Summary of the lessons learnt from the survey
Early appointments were appreciated by the participants aged 50 and
over
Holding health examinations in each town centre led to good
response rates
Flexible appointment dates and times led to good the response rates
Measuring the waist and hip circumference just after measuring
weight and height was found most appropriate and acceptable by
participants
Carrying out an interview, followed by health examination
measurements and then the collection of blood was acceptable to
the participants
Explanations of the whole process prior to and during the survey
made the experience more enjoyable for the participants
Explanations of the participants’ measurements at the end of their
health examinations were appreciated by the participants
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inaccurate data and may not have fasted as advised. Also,
participants who had normal FBG levels but abnormal post-
prandial levels (indicative of pre-diabetes or diabetes) could
have been missed by the study.
Conclusion
This protocol sets out the methods used in a prevalence
study in Malta, which provided essential data that will be
used to develop an up-to-date national policy on diabetes
(which will include the development of prevention strategies).
The study utilized validated measurement tools and was gen-
erally found to be acceptable by the participants. The study
provided data on the national prevalence of diabetes, IFG,
IGT, obesity, regular physical activity, alcohol consumption
and tobacco consumption, together with information on
the important associations between the potential risk factors
and diabetes, and, for the ﬁrst time, information on the gen-
etics associated with the development of diabetes.
Supplementary material
The supplementary material for this article can be found at
https://doi.org/10.1017/gheg.2016.18.
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